共 50 条
- [21] Multiple-cohort analysis investigating FGFR3 alteration as a predictor of non-response to neoadjuvant pembrolizumab (pembro) in muscle-invasive bladder cancer (MIBC)ANNALS OF ONCOLOGY, 2019, 30Necchi, A.Madison, R.Chung, J.Raggi, D.Briganti, A.Montorsi, F.Boormans, J. L.Liu, Y.De Jong, J. J.Chung, J.Black, P. C.Ross, J. S.Ali, S. M.Davicioni, E.Gibb, E. A.
- [22] Comprehensive biomarker analyses and updated results of PURE-01 study: Neoadjuvant pembrolizumab (pembro) in muscle-invasive urothelial bladder carcinoma (MIBC)ANNALS OF ONCOLOGY, 2018, 29 : 305 - 305Necchi, A.Briganti, A.Raggi, D.Luciano, R. 'Colecchia, M.Massa, S.Giannatempo, P.Colombo, R.Gallina, A.Salvioni, R.Mortarini, R.Montorsi, F.Madison, R.Ali, S. M.Ross, J. S.Chung, J.Anichini, A.
- [23] Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Balar, Arjun VasantMilowsky, Matthew I.O'Donnell, Peter H.Alva, Ajjai ShivaramKollmeier, MarisaRose, Tracy L.Pitroda, SeanKaffenberger, Samuel D.Rosenberg, Jonathan E.Francese, KaitlynHochman, TsiviaGoldberg, Judith D.Griglun, SarahLeis, DaynaSteinberg, Gary D.Wysock, JamesSchiff, Peter B.Sanfilippo, Nicholas J.Taneja, SamirHuang, William C.
- [24] Association of an immune gene signature with pathologic response and outcome after neoadjuvant pembrolizumab (pembro), compared to neoadjuvant chemotherapy (NAC), in muscle-invasive bladder cancer (MIBC)JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)Necchi, AndreaRaggi, DanieleBriganti, AlbertoFare, ElenaGiannatempo, PatriziaMarandino, LauraBianchi, MarcoGallina, AndreaSalonia, AndreaGandaglia, GiorgioFossati, NicolaCapitanio, UmbertoMontorsi, FrancescoBoormans, Joost L.Liu, Yangde Jong, JoepBlack, Peter C.Dittamore, RyanDavicioni, ElaiGibb, Ewan
- [25] ASSOCIATION OF AN IMMUNE-GENE SIGNATURE WITH PATHOLOGIC RESPONSE AND OUTCOME AFTER NEOADJUVANT PEMBROLIZUMAB (PEMBRO), COMPARED TO NEOADJUVANT CHEMOTHERAPY (NAC), IN MUSCLE-INVASIVE BLADDER CANCER (MIBC)JOURNAL OF UROLOGY, 2020, 203 : E841 - E841Necchi, AndreaRaggi, DanieleBriganti, AlbertoFare, ElenaGiannatempo, PatriziaMarandino, LauraGallina, AndreaBianchi, MarcoSalonia, AndreaGandaglia, GiorgioFossati, NicolaCapitanio, UmbertoMontorsi, FrancescoBoormans, JoostLiu, Yangde Jong, JoepDittamore, RyanDavicioni, ElaiBlack, PeterGibb, Ewan
- [26] Circulating tumor DNA (ctDNA) clearance with neoadjuvant durvalumab (D) plus tremelimumab (T) plus enfortumab vedotin (EV) for cisplatin-ineligible muscle-invasive bladder cancer (MIBC) from the safety run-in cohort of the phase III VOLGA trialANNALS OF ONCOLOGY, 2024, 35 : S1140 - S1140Drakaki, A.Powles, T. B.Wang, Y.Bupathi, M.Joshi, M.Fleming, M. T.de Liano Lista, A. GomezMorales Barrera, R.Pili, R.Boulos, S.Shrestha, Y.
- [27] Study EV-103: New cohorts testing enfortumab vedotin alone or in combination with pembrolizumab in muscle invasive urothelial cancerJOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)Hoimes, Christopher J.Rosenberg, Jonathan E.Petrylak, Daniel PeterCarret, Anne-SophieSasse, CarolynChaney, Marya F.Flaig, Thomas W.
- [28] First survival outcomes and additional secondary analyses from PURE-01: Pembrolizumab (pembro) before radical cystectomy (RC) in muscle-invasive urothelial bladder carcinoma (MIBC).JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)Necchi, AndreaBandini, MarcoGallina, AndreaBianchi, MarcoRaggi, DanieleFare, ElenaMessina, AntonellaChung, JonAli, Siraj MahamedMadison, RussellAnichini, AndreaColecchia, MaurizioGandaglia, GiorgioFossati, NicolaScuderi, Simone Luca AntonioPederzoli, FilippoColombo, RenzoBriganti, AlbertoMontorsi, Francesco
- [29] FIRST SURVIVAL OUTCOMES AND ADDITIONAL SECONDARY ANALYSES FROM PURE-01: PEMBROLIZUMAB (PEMBRO) BEFORE RADICAL CYSTECTOMY (RC) IN MUSCLE-INVASIVE UROTHELIAL BLADDER CARCINOMA (MIBC)JOURNAL OF UROLOGY, 2019, 201 (04): : E840 - E841Necchi, AndreaBandini, MarcoGallina, AndreaBianchi, MarcoRaggi, DanieleMessina, AntonellaChung, JonAli, SirajRoss, JeffreyAnichini, AndreaAnichini, AndreaColecchia, MaurizioGandaglia, GiorgioFossati, NicolaScuderi, SimonePederzoli, FilippoSalonia, AndreaColombo, RenzoBriganti, AlbertoMontorsi, Francesco
- [30] Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)Petrylak, Daniel P.Flaig, Thomas W.Mar, NataliyaGourdin, Theodore StewartSrinivas, SandyRosenberg, Jonathan E.Guseva, MariaYu, YaoNarayanan, SujataHoimes, Christopher J.